- Home
- ACLX vs PCVX Comparison
ACLX vs PCVX Comparison
Compare ACLX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- PCVX
- Stock Information
- Founded
- ACLX 2015
- PCVX 2013
- Country
- ACLX United States
- PCVX United States
- Employees
- ACLX N/A
- PCVX N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- PCVX Health Care
- Exchange
- ACLX Nasdaq
- PCVX Nasdaq
- Market Cap
- ACLX 4.1B
- PCVX 4.4B
- IPO Year
- ACLX 2022
- PCVX 2020
- Fundamental
- Price
- ACLX $71.28
- PCVX $32.29
- Analyst Decision
- ACLX Strong Buy
- PCVX Strong Buy
- Analyst Count
- ACLX 14
- PCVX 10
- Target Price
- ACLX $114.75
- PCVX $136.50
- AVG Volume (30 Days)
- ACLX 522.3K
- PCVX 1.3M
- Earning Date
- ACLX 08-07-2025
- PCVX 08-06-2025
- Dividend Yield
- ACLX N/A
- PCVX N/A
- EPS Growth
- ACLX N/A
- PCVX N/A
- EPS
- ACLX N/A
- PCVX N/A
- Revenue
- ACLX $56,979,000.00
- PCVX N/A
- Revenue This Year
- ACLX N/A
- PCVX N/A
- Revenue Next Year
- ACLX $108.81
- PCVX N/A
- P/E Ratio
- ACLX N/A
- PCVX N/A
- Revenue Growth
- ACLX N/A
- PCVX N/A
- 52 Week Low
- ACLX $47.86
- PCVX $27.66
- 52 Week High
- ACLX $107.37
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- ACLX 52.20
- PCVX 47.44
- Support Level
- ACLX $69.00
- PCVX $30.69
- Resistance Level
- ACLX $74.74
- PCVX $33.14
- Average True Range (ATR)
- ACLX 3.47
- PCVX 1.26
- MACD
- ACLX -0.19
- PCVX 0.10
- Stochastic Oscillator
- ACLX 56.94
- PCVX 59.23
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.